06855.HK
Ascentage Pharma Group International
HKSE · Healthcare · Biotechnology · CN
HKD 35.00
+1.74%Year over year
Reported trailing growth
- Revenue
- -11.8%
- EBITDA
- —
- EBIT
- —
- EPS
- -64.2%
- Free cash flow
- -4.1%
- Operating cash flow
- -12.2%
Forward estimates
Based on analyst estimates
- Revenue
- +24.6%
- EBITDA
- +70.7%
- EPS
- +64.9%
Three-year CAGR
- Revenue
- +38.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026